Quantum BioPharma Statistics
Total Valuation
QNTM has a market cap or net worth of $16.41 million. The enterprise value is $8.79 million.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, after market close.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
QNTM has 1.93 million shares outstanding. The number of shares has increased by 86.67% in one year.
| Current Share Class | 1.93M |
| Shares Outstanding | 1.93M |
| Shares Change (YoY) | +86.67% |
| Shares Change (QoQ) | +115.92% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.57 |
| P/TBV Ratio | 2.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.80, with a Debt / Equity ratio of 0.06.
| Current Ratio | 1.80 |
| Quick Ratio | 1.65 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -493.02 |
Financial Efficiency
Return on equity (ROE) is -127.76% and return on invested capital (ROIC) is -83.52%.
| Return on Equity (ROE) | -127.76% |
| Return on Assets (ROA) | -58.82% |
| Return on Invested Capital (ROIC) | -83.52% |
| Return on Capital Employed (ROCE) | -155.92% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$835,454 |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -85.96% in the last 52 weeks. The beta is 0.85, so QNTM's price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | -85.96% |
| 50-Day Moving Average | 6.15 |
| 200-Day Moving Average | 5.96 |
| Relative Strength Index (RSI) | 51.50 |
| Average Volume (20 Days) | 1,434,764 |
Short Selling Information
The latest short interest is 47,433, so 2.46% of the outstanding shares have been sold short.
| Short Interest | 47,433 |
| Short Previous Month | 49,138 |
| Short % of Shares Out | 2.46% |
| Short % of Float | 2.96% |
| Short Ratio (days to cover) | 0.22 |
Income Statement
| Revenue | n/a |
| Gross Profit | -141,770 |
| Operating Income | -16.28M |
| Pretax Income | n/a |
| Net Income | -14.20M |
| EBITDA | -15.79M |
| EBIT | -16.28M |
| Earnings Per Share (EPS) | -$12.49 |
Full Income StatementBalance Sheet
The company has $7.20 million in cash and $672,809 in debt, giving a net cash position of $6.53 million or $3.39 per share.
| Cash & Cash Equivalents | 7.20M |
| Total Debt | 672,809 |
| Net Cash | 6.53M |
| Net Cash Per Share | $3.39 |
| Equity (Book Value) | 10.44M |
| Book Value Per Share | 5.79 |
| Working Capital | 5.37M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.88 million and capital expenditures -$1.00 million, giving a free cash flow of -$7.88 million.
| Operating Cash Flow | -6.88M |
| Capital Expenditures | -1.00M |
| Free Cash Flow | -7.88M |
| FCF Per Share | -$4.09 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |